Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults

NCT05633446 is registered in ClinicalTrials.gov with Gylden Pharma Ltd as lead sponsor.

NCT NCT05633446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05633446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults
Lead sponsor
Gylden Pharma Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 1, 2026
Enrollment
110 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid-19, sars-cov-2 infection